News | February 08, 2025
Aurbindo Pharma posts Q3 FY25 profit at Rs. 846 Cr
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Growth markets revenue increased by 44 YoY to Rs. 812 crore
USFDA completes PAI of Lupin’s biotech facility in Pune
The product is expected to be launched in Q3FY25
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
